Cel-Sci Long Awaited Head And Neck Trial Phase III: Data Locked

12/15/20

By Fosco Research, SeekingAlpha

Summary

  • Data lock has been announced, and top line data is to be expected within a few weeks.
  • Trial duration hints towards longer survival than Standard of Care.
  • No other drug can explain this long survival.
  • Cel-Sci might have a potential blockbuster drug in the making.

Introduction

Cel-Sci Corporation (NYSEMKT:CVM) is a biotech company running a Phase III clinical trial with its flagship compound, Multikine.

In every manner that we are looking at this Phase III trial, it looks like patients enrolled in have been living longer than they should under Standard of Care. There are also other elements that we will expose further that make us believe that the trial has a high probability of being successful.

The company has announced that the last event required to complete the trial had happened by the end of April 2020. The data lock phase has taken 7 months, more than everyone had been anticipating due to COVID-19 constraints and for the length of the process required to gather the data of this 10 years lasting multi-centre and multi-country trial.

This article is an update of this previously published article back in July 2019. Because since our previous article, some key events have happened, we thought that reviewing our initial analysis was worthwhile. In addition, we refined our research with a lot of additional information.

Back in that time, we were waiting for the last event to happen to get enough datapoints for the data analysis phase as per the Statistical Analysis Plan (SAP). It happened unexpectedly longer than anticipated (in April 2020), which was rather a good sign as proof patients were living longer.

On Monday, December 7th of 2020, Cel-Sci announced that its long awaited data Lock for its Phase III clinical trial had finally happened. Cel-Sci did not provide any date for this. This means that Top line Data Analysis shall be disclosed in a few weeks from now.

We believe that the risk-reward ratio is at an incredible level. We will explain why in the following lines.

Analysis

a - Survival Analysis Update

Please refer to our previously published article for the details of the company and the design of the trial.

It took two years more than expected to get to the last event to occur. In the meantime, Cel-Sci management had stated on a regular basis that the 298th event had not occurred. The statement "the longer we wait for the 298th to occur, the more likely it shows Multikine is effective" has been used by investors and Cel-Sci management on a regular basis.

The SEER database compiles survival for many sites and spans many years. We applied inclusion criteria for the Oral Cavity, excluding BoT. We updated our previous analysis with the newest data from SEER. Please review our description including the inclusion criteria which are critical for understanding this survival analysis. In the new analysis, we included years from 2008 until 2016, which corresponds approximately to the years patients were recruited for Cel-Sci clinical trial.

Fig. 1 : Total Resection + CRT/ RT Survival for this cancer population. Source SEER software.

Survival of cancer patients going through S-RT or S-CRT is 57.4% at Year 3 and 48.2% at Year 5 in America.

In this international clinical trial, we expect patients under Standard of Care to show a poorer survival pattern than the US one: one only has to look at existing survival studies in literature from India, Bulgaria, Thailand etc.

Calculation will show that, with an overall survival close to 57% at year 3, the endpoint should have been reached at least 16 months earlier than it has. Therefore, we can already conclude that patients are living much longer than they should.

READ FULL ARTICLE HERE